首页 | 本学科首页   官方微博 | 高级检索  
     


Expression of myelin basic protein and glial fibrillary acidic protein genes in human glial tumors
Authors:V. V. Dmitrenko  O. I. Boyko  K. O. Shostak  A. V. Beletskii  T. A. Malisheva  M. I. Shamayev  V. M. Klyuchka  V. D. Rozumenko  Y. P. Zozulya  V. M. Kavsan
Affiliation:(1) Institute of Molecular Biology and Genetics of the National Academy of Sciences of Ukraine, vul. Akad. Zabolotny 150, Kyiv, 03680, Ukraine;(2) Romodanov Institute of Neurosurgery, Academy of Medical Sciences of Ukraine, vul. Manuyil’sky 32, Kyiv, 04050, Ukraine
Abstract:Analysis of the expression of genes encoding myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in human glial tumors was carried out for determination of the expression specificity of these genes according to tumor types and their malignancy. Low levels of MBP mRNA in astrocytoma specimens of malignancy grades II-IV and significantly higher levels in perifocal zones adjacent to them have been determined by Northern hybridization. Diffuse astrocytomas and anaplastic astrocytomas are characterized mostly by a low level of MBP gene expression and high level of GFAP gene expression, but distinct subtypes of diffuse and anaplastic astrocytomas with a high level of GFAP gene expression can also be detected that may be the reflection of different oncogenic pathways. Very low levels or even absence of MBP mRNA were revealed in oligodendroglioma and all oligoastrocytomas. Thus, Northern hybridization data are correlated with serial analysis of gene expression (SAGE). Obtained results show that MBP is a nonspecific marker for tumors of oligodendroglial origin, but determination of relative levels of MBP and GFAP mRNAs may be useful for glial tumor recognition. In such a way, these two genes together with YKL-40 and TSC-22, which we found previously, can be included into the gene panel for determination of so-called “gene signatures” of brain tumors. However, strict requirements in relation to a clinical value of these “gene signatures” cannot be formulated without verifying them on a large number of clinical samples of tumors and valid control.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号